Jobs
-
Swedish device developer Iconovo has received a $350,000 grant from Swedish innovation agency Vinnova for continued development of the company’s ICOone unit-dose disposable dry powder inhaler, the company said. Iconovo, which is located at the… Read more . . .
-
RODES, Inc. and Ligand Pharmaceuticals have announced global license and supply agreements for three products in development using Ligand’s Captisol formulation technology, including intranasal budesonide/azelastine for the treatment of allergic rhinitis. RODES will pay all… Read more . . .
-
Aptar Pharma will introduce its new DF30Plus metering valve at this year’s Drug Delivery to the Lungs conference, the company said. The DF30Plus is based on the company’s widely-used DF30 metering valve and features a… Read more . . .
-
Enrollment has begun for a Phase 1 clinical study of Acorda Therapeutics’ CVT-427 zolmitriptan DPI for the treatment of migraines, the company said. The single ascending dose study, which is expected to enroll 32 healthy… Read more . . .
-
US inhaled drug developer InCarda Therapeutics has launched a subsidiary business in Australia in preparation for its first clinical trial, which is scheduled for the first half of 2016, the company said. According to InCarda,… Read more . . .
-
Inhaler monitoring company Propeller Health has announced that it will develop a sensor for GSK’s Ellipta dry powder inhaler for use in gathering inhaler usage data during clinical trials. GSK also has the option to… Read more . . .
-
Less than a week after the FDA approved Adapt Pharma’s Narcan naloxone nasal spray for the treatment of opioid overdose, the agency has issued a Complete Response Letter to Indivior’s NDA for its naloxone nasal… Read more . . .
-
According to Circassia Pharmaceuticals, the UK has approved the company’s generic fluticasone propionate MDI for the treatment of asthma under the European decentralized procedure. The MAA includes the same three strengths (50µg, 125µg and 250µg… Read more . . .
-
According to the FDA, GlaxoSmithKline has reported that 20 mg and 5 mg dosages of its Imitrex nasal spray for the treatment of migraine headaches will be unavailable until February 2016 due to an API… Read more . . .
-
MannKind Corporation has announced the resignation of Hakan Edstrom, who was the company’s President and CEO, as well as a director. In the wake of the resignation, Alfred Mann has been appointed interim CEO, effective… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden